FDA Indicates Potential Full Approval for Eisai & Biogen’s Leqembi Ahead of Adcomm
The documents come just two days before an advisory committee is scheduled to vote on the Alzheimer’s drug.
The Home of the Life Sciences Industry
FibroGen’s Duchenne Muscular Dystrophy Drug Fails Phase III Trial
In a late-stage study of non-ambulatory patients with DMD on background corticosteroids, pamrevlumab failed to meet the primary endpoint for upper limb performance.
